Trends of drug use with suggested shortages and their alternatives across 41 real world data sources and 18 countries in Europe and North America
Author:
Pineda-Moncusí Marta, Rekkas Alexandros, Pérez Álvaro Martínez, Leis Angela, Gomez Carlos Lopez, Bruninx Erwin, Maljković Filip, Rodeiro Jordi, Franz Michael, Mayer Miguel-Angel, Eleangovan Neva, Natsiavas Pantelis, Şen Selçuk, Cooper Steven, Reisberg Sulev, Manlik Katrin, Sánchez-Sáez Francisco, del Pino Beatriz, Uribe Albert PratsORCID, Üresin Ali Yağız, Bastić Ana Danilović, Rodrigues Ana Maria, Palomar-Cros Anna, Verbiest Annelies, Erdoğan Barış, Keuthage Carina Dinkel-, Torre Carmen Olga, de Beukelaar Caroline, Eteve-Pitsaer Caroline, Gonçalves Cátia F., de Palma Costantino, Gavina Cristina, Dedman Daniel, Price David Brendan, Balan Denisa Gabriela, Enders Dirk, Henke Elisa, Scheurwegs Elyne, Callewaert Emma, Martínez Encarnación Pérez, Tan Eng HooiORCID, Fey Eric, Prasser Fabian, Staelens Frank, Nyberg FredrikORCID, Candore Gianmario, Mestdach Gianny, Shachaf Hadas, Li Huiqi, Reinecke Ines, López-Sánchez Irene, de la Cruz Bertolo Javier, Evers Jelle, Firmino-Machado João, Wastesson Jonas, Bermúdez Juan Luis Cruz, Ramírez-Anguita Juan Manuel, Porkka KimmoORCID, Johnell Kristina, Cool Lieselot, Kiss Loretta Zsuzsa, Moscetti Luca, Merkelbach Manon, Canelas-Pais Mariana, Dominici Massimo, Szilcz Máté, Puntoni Matteo, Mosseveld Mees, Tadrous Mina, Bové Mona, Rappoport NadavORCID, Barrio Noelia García, Ettala Otto, Baili Paolo, Pulido Pau Pericàs, Mayo Paula Rubio, Prinsen Peter, Norris Raeleesha, Claire Ravinder, Lillini Roberto, Lazzarelli Silvia, Duarte-Salles TalitaORCID, Taveira-Gomes Tiago, Jansen Tim, Keilholz Ulrich, Li Xintong, Prieto-Alhambra DanielORCID, Rijnbeek Peter R., Burkard Theresa
Abstract
AbstractImportanceDrug production not meeting the demand leaves affected patients in a vulnerable position.ObjectiveTo describe incidence and prevalence of medicines with suggested shortages in at least one European countryDesignWe performed a descriptive cohort study between 2010 in a network of databases which have mapped their data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).SettingSetting included primary care, secondary care, and various disease registries whose previously collected data was leveraged.ParticipantsWe included all patients with at least 365 days of history on the database.ExposuresWe investigated all medicines with a suggested shortage in at least one European country for more than 365 days (n=18). Furthermore, we assessed their alternatives as well (n=39).Main outcomes and measuresWe estimated annual incidence rates and period prevalence of all medicines with suggested shortages and their alternatives. A drop in incidence or prevalence of more than 33% after the shortage announce by the European Medicines Agency was considered confirmation of a shortage.ResultsAmong 41 databases from Europe and the United States, we observed shortages according to incidence for 12 drugs and shortages according to prevalence for 4 drugs. The drugs varenicline, cetrorelix, and amoxicillin plus clavulanate were in shortage in the most countries.Conclusion and relevanceWe compiled and analysed data of annual incidence and prevalence of 57 medicines among 41 databases in Europe and the United States. We detected shortages of several drugs and suggest monitoring and stewardship for drug availability.
Publisher
Cold Spring Harbor Laboratory
|
|